BACKGROUND:Bioactive glass has been largely reported to have perfect clinical results in the bone nonunion and fracture healing, but its effect during spinal fusion progress is rarely reported. OBJECTIVE:To explore the safety and effectiveness of anterior cervical discectomy and fusion by cervical cage with bioactive glass METHODS:A total of 68 cases of cervical spondylosis myelopathy were treated with single level anterior cervical discectomy and fusion. Their clinical data were retrospectively analyzed. Al the cases underwent polyetheretherketone cervical cage with autogenous bone (n=32, control group) or bioactive glass (n=32, experimental group). The bone fusion, neurological functional recovery, intervertebral height, change of cervical curve and wound complications in the two groups was recorded and analyzed. RESULTS AND CONCLUSION:Neurological improvement had no difference between the two groups and there was no complication about wound, such as infection and delayed healing. The average rate of bone fusion was 97%in the control group while 94%in the experiment group 3 months after operation which had no significant differences. Six months after operation, al cases gained bone fusion. The intervertebral height and change of cervical curve both maintained wel in the two groups within 3, 6, 12 months after operation which had no significant differences between the two groups. So, anterior cervical discectomy and fusion by cervical cage with bioactive glass is safe and effective.%背景：已有文献报道生物活性玻璃在骨不连、骨折愈合过程中有较佳的临床疗效，但其在脊柱骨融合过程中的效果鲜有报道。 目的：观察生物活性玻璃联合颈椎椎间融合器在颈椎前路椎间融合中应用的安全性和有效性。 方法：回顾性分析68例颈椎前路单节段椎间融合患者资料，全部病例均采用聚醚醚酮材料椎间融合器，其中内填充自体松质骨植骨32例为对照组，采用生物活性玻璃填充36例为实验组。随访观察两组植骨融合、神经功能恢复、椎间隙高度和颈椎生理曲度及伤口并发症等情况。 结果与结论：两组患者的神经功能改善效果相当，均未出现伤口感染及延迟愈合等并发症。治疗3个月时，实验组与对照组骨性融合率分别为94%，97%，组间比较差异无显著性意义；治疗6个月时全部融合。两组随访3，6，12个月时椎间隙高度和颈椎曲度指数均获得良好维持，组间比较差异无显著性意义。提示生物活性玻璃联合颈椎椎间融合器在颈椎前路椎间融合中有良好的临床安全性和有效性。
展开▼
